Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5426)	9/28/1998 2:59:00 PM
From: Steve Fancy	of 6136

Vertex Pharma/Glaxo Protease Inhibitor Effective In Study Dow Jones Newswires SAN DIEGO -- Vertex Pharmaceuticals Inc. (VRTX) and Glaxo Wellcome PLC's (GLX) Agenerase HIV protease inhibitor may be potent and generally well-tolerated with Epivir and Retrovir in a Phase III clinical trial. In a press release Monday, Vertex said data from interim 16-week data showed that 88% of patients taking triple therapy with Agenerase, Epivir and Retrovir achieved viral load below the limit of detection of standard assets. The company said an additional analysis showed that 59% of patients who received the triple therapy regimen achieved viral load below the limit of detection of an investigational ultrasensitive assayl. Patients received dosages twice a day. Vertex said side effects from Agenerase include nausea, vomiting, fatigue and headache. Vertex researches, develops and commercializes small molecule drugs for viral diseases, multidrug resistance in cancer, hemoglobin and autoimmune disorders. Glaxo Wellcome researches, develops and markets pharmaceuticals.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next